Since its December 2025 IPO, Medline had publicly championed its 2,400-member quality control team as a guarantor of product safety. That narrative fractured on June 2, 2026, when the FDA released a May 28 warning letter addressed to CEO Boyle. The document revealed that the company had repeatedly isolated objectionable microorganisms in finished products nine times between June 2023 and August 2025, despite prior warnings issued in January 2025.
Regulatory scrutiny exposed that Medline had shuttered specific facilities last October due to these contamination issues—a fact that had not been disclosed to investors. Reed Kathrein, the partner leading the Hagens Berman probe, is now focusing on whether the company deliberately hid these serious safety concerns to maintain its market standing. The firm is currently soliciting input from investors and potential whistleblowers who may possess non-public information regarding the company's internal compliance failures.
Comments (0)
No comments yet. Be the first!